G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
125 hedge funds and large institutions have $434M invested in G1 Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
27% more capital invested
Capital invested by funds: $343M → $434M (+$91.4M)
6% more funds holding
Funds holding: 118 → 125 (+7)
9% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
64% less call options, than puts
Call options by funds: $2.54M | Put options by funds: $7.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$5.53M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$5.2M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$4.46M |
| 4 |
BlackRock
New York
|
+$3.93M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
+$3.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$50.3M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$26.1M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$8.34M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$7.09M |
| 5 |
Millennium Management
New York
|
-$6.18M |
GTHX Hedge Fund Activity: Q4 2020 in Review
125 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q4 2020, worth a combined $434M — up 27% from $343M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GTHX positions and 10 closed out — a net gain of 7 holders — while 47 added to existing stakes and 43 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $5.53M. The largest seller was Fidelity Investments, cutting an estimated $50.3M.
- 125 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q4 2020, up from 118 in Q3 2020.
- Funds reported $434M of G1 Therapeutics, Inc. Common Stock stock for Q4 2020, up 27% quarter-over-quarter.
- 17 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q4 2020 and 10 closed out, a net change of +7 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q4 2020 was Two Sigma Advisers, an estimated $5.53M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q4 2020 was Fidelity Investments, an estimated $50.3M sold.
Based on aggregated 13F filings for Q4 2020.